,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-11-29 09:00:00,"Medical devices major, St. Jude Medical ( STJ ) recently won the European CE Mark approval for its line of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) named Assura.",0.9404837489128113,0.016164841130375862,0.043351419270038605,positive,0.9243189096450806
1,2012-11-29 09:00:00,"The three latest Assura devices available in Europe are Quadra Assura CRT-D, Unify Assura CRT-D and Fortify Assura ICD.",0.07842695713043213,0.004369450733065605,0.9172035455703735,neutral,0.07405750453472137
2,2012-11-29 09:00:00,The Assura product line gained the approval of the U.S. Food and Drug Administration in May 2012.,0.6644728183746338,0.010178928263485432,0.32534828782081604,positive,0.6542938947677612
3,2012-11-29 09:00:00,The Assura devices from St. Jude Medical's Cardiac Rhythm Management (CRM) division are already garnering revenues for the company in the domestic market.,0.9362562894821167,0.01619148813188076,0.04755235090851784,positive,0.9200648069381714
4,2012-11-29 09:00:00,The CE Mark approval will position the portfolio to extract incremental revenues in the European market.,0.8449597954750061,0.0104097630828619,0.14463041722774506,positive,0.8345500230789185
5,2012-11-29 09:00:00,"The target for Assura product line are patients prone to sudden cardiac death (SCD) due to abnormally fast, potentially fatal cardiac rhythms and patients at risk of heart failure.",0.020633691921830177,0.020764630287885666,0.9586016535758972,neutral,-0.00013093836605548859
6,2012-11-29 09:00:00,The Assura ICDs and CRT-Ds address this problem and offer precise solutions.,0.1220308467745781,0.006139372941106558,0.8718297481536865,neutral,0.1158914715051651
7,2012-11-29 09:00:00,"Statistics from meta-analysis conducted by the Sudden Cardiac Arrest Thought Leadership Alliance (SCATLA) indicate that about 180,000-450,000 people are annually affected by sudden cardiac death in Europe.",0.048294443637132645,0.5857285261154175,0.36597707867622375,negative,-0.5374341011047363
8,2012-11-29 09:00:00,"Hence, there is considerable scope for penetration in the European market.",0.7491529583930969,0.010784592479467392,0.24006247520446777,positive,0.7383683919906616
9,2012-11-29 09:00:00,The Assura portfolio will include advanced sensing options which can reduce the probability of untimely shocks.,0.4664608836174011,0.008202945813536644,0.5253360867500305,neutral,0.4582579433917999
10,2012-11-29 09:00:00,"The new device comes with SecureSense RV Lead Noise Discrimination, CorVue congestion monitoring and expanded ShockGuard Technology.",0.6552851796150208,0.011403030715882778,0.3333118259906769,positive,0.643882155418396
11,2012-11-29 09:00:00,The SecureSense RV Lead Noise Discrimination can identify lead related problems for improved patient safety.,0.8253504633903503,0.021754546090960503,0.1528950333595276,positive,0.8035959005355835
12,2012-11-29 09:00:00,This algorithm distinguishes between lead noises and actual ventricular fibrillation or ventricular tachycardia that requires life saving treatment.,0.03169618546962738,0.010862396098673344,0.9574414491653442,neutral,0.02083379030227661
13,2012-11-29 09:00:00,This is possible due to reduced uncertainties associated with lead issues.,0.6903879642486572,0.010865263640880585,0.298746794462204,positive,0.679522693157196
14,2012-11-29 09:00:00,The ShockGuard technology works on a parallel note by distinguishing between benign arrhythmias and rhythms that necessitate defibrillation therapy.,0.19086217880249023,0.009828849695622921,0.7993088960647583,neutral,0.18103332817554474
15,2012-11-29 09:00:00,We have a long-term 'Neutral' recommendation on St. Jude Medical which carries a short-term Zacks #3 Rank (Hold).,0.03464926779270172,0.04834320396184921,0.917007565498352,neutral,-0.013693936169147491
16,2012-11-29 09:00:00,"While the company is battling pricing pressure and declining volumes in the domestic ICD market, it continues to have a substantial market share in the worldwide CRM market along with Boston Scientific ( BSX ) and Medtronic ( MDT ).",0.705928385257721,0.05572563782334328,0.2383459508419037,positive,0.650202751159668
17,2012-11-29 09:00:00,"With a slew of new products, the big three players in the ICD market are striving to gain market share, despite the challenging business environment and a sluggish CRM market.",0.9431449770927429,0.018034301698207855,0.03882071003317833,positive,0.9251106977462769
18,2012-11-29 09:00:00,These players are also exploring new avenues of growth beyond the mature pacemaker and ICD markets.,0.6166397929191589,0.010006483644247055,0.3733536899089813,positive,0.6066333055496216
19,2012-11-29 09:00:00,"With gradual stability in the ICD market, these players should be able to revive their top line.",0.9302040338516235,0.014873664826154709,0.05492231622338295,positive,0.9153303503990173
20,2012-11-29 09:00:00,To read this article on Zacks.com click here.,0.01796119473874569,0.0192450862377882,0.9627937078475952,neutral,-0.001283891499042511
21,2012-11-29 09:00:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
